Iph4102-201
WebIPH4102-201: National Competent Authority: Italy - Italian Medicines Agency: Clinical Trial Type: EEA CTA: Trial Status: Ongoing: Date on which this record was first entered in the … Web12 jun. 2024 · IPH4102 is a humanized first-in-class anti-KIR3DL2 monoclonal antibody designed to deplete KIR3DL2-expressing cells via antibody-dependent cell-cytotoxicity (ADCC) and phagocytosis.
Iph4102-201
Did you know?
Web15 jun. 2024 · IPH4102 is Innate Pharma’s wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells. 25 patients, with a median age of 71 years old and a median number of four prior systemic treatments, were evaluable for safety (10 dose levels: 0.0001 to 10 mg/kg). Web1 jun. 2024 · Background IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form,...
Web12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der … Web25 jun. 2024 · IPH4102 is a humanised, first-in-class, monoclonal antibody that targets KIR3DL2, a cell surface protein widely expressed in cutaneous T-cell lymphoma, and …
Web12 apr. 2024 · Protocol: IPH4102-201: TELLOMAK: An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with … Web29 nov. 2024 · Aims: Sezary Syndrome (SS) is the most aggressive form of cutaneous T cell lymphoma (CTCL), characterized with high blood involvement and expression o…
Web13 okt. 2016 · IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed to trigger killing of CTCL cancer cells, an orphan disease. This group of rare cutaneous lymphomas of T...
Web本发明涉及与分子支架共价结合的多肽，其使得两个或更多个肽环在支架的连接点之间相对。特别地，本发明描述了作为结合 ... rain riskWebBackground: IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its … rain riteWeb13 sep. 2024 · IPH4102 in PTCL were presented at 2024 International Conference on the Malignant Lymphoma (ICML) in June 2024. o The outcome of the first stage of the MF and PTCL cohorts is expected in the second half of 2024. Initial efficacy data are expected starting in 2024. o Study results from the Phase I dose-escalation and expansion trial of … rain rhymes in kannadaWeb26 okt. 2016 · IPH4102 is Innate Pharma's wholly-owned, first-in-class anti-KIR3DL2 humanized therapeutic antibody, designed to trigger immune cell-mediated killing of CTCL cancer cells. cvs price scannerWebAn open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma. 2024-003969-33 Databank klinische proeven rain rn150 9vWebInnate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the design of the “TELLOMAK” Phase II trial and new preclinical data supporting the potential of IPH4102 in peripheral T-cell lymphoma (“PTCL”) as well as Adult T-cell leukemia/lymphoma (“ATLL”) will be presented at the International Conference on … rain rihanna lyricsWeb12 jul. 2024 · IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma Carrie Van Der Weyden , Martine Bagot , Paul Neeson , Phil K. Darcy & H. Miles Prince rain risk 2